Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine, discusses how the use of adjuvant immunotherapy has affected the resectable non–small cell lung cancer (NSCLC) treatment paradigm, as well as unanswered questions in this arena.